In agreement with the cleaved caspase-3 assay, we observed a combination effect of ixazomib plus venetoclax in CLL cells from treatment naïve patients (Fig. 4d, left). The gene discussed is CASP3; the disease is B-cell chronic lymphocytic leukemia.